Treatment of cancer with dual targeting of CD47 and EGFR

Patent metadata

Field	Value
Publication number	US-12037402-B2
Application number	US-202117411953-A
Country	US
Kind code	B2
Filing date	Aug 25, 2021
Priority date	Dec 11, 2015
Publication date	Jul 16, 2024
Grant date	Jul 16, 2024

Abstract

Methods are provided for targeting cells for depletion, including, without limitation, cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS and BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.

First claim

What is claimed is:

1. A method for immunodepletion of EGFR-expressing squamous cell carcinoma of the head and neck (SCCHN) cells in which an activating mutation in one or more of KRAS, NRAS and BRAF is present in an individual human in need thereof, the method comprising:
(a) administering to the individual: a dose of 1 mg/kg of an antibody that binds to CD47 and blockades CD47 activity; and after a period of time effective for an increase in reticulocyte production;
(b) administering (i) an antibody that binds to CD47 and blockades CD47 activity, and (ii) an antibody that specifically binds to epidermal growth factor receptor, wherein (i) and (ii) are administered in a dose effective to increase immunodepletion of the EGFR-expressing SCCHN cells, wherein depletion of the SCCHN cells is enhanced relative to the depletion observed with a monotherapy of (i) an antibody that blockades CD47 activity or (ii) an anti-EGFR antibody.

2. The method of claim 1 , wherein the antibody that specifically binds to EGFR is an antagonist of EGFR signaling pathway.

3. The method of claim 1 , wherein the antibody that specifically binds to EGFR is a non-antagonist of EGFR signaling pathway.

4. The method of claim 1 , wherein the anti-CD47 antibody of step (b) comprises an IgG4 Fc region.

5. The method of claim 4 , wherein the anti-CD47 antibody comprises a variable heavy (VH) region containing the VH complementarity regions, CDR1, CDR2 and CDR3, respectively set forth in SEQ ID NO:1, 2 and 3; and a variable light (VL) region containing the VL complementary regions, CDR1, CDR2 and CDR3, respectively set forth in in SEQ ID NO:4, 5, 6.

6. The method of claim 1 , further comprising administering an effective dose of an erythropoietin stimulating agent to increase patient hematocrit.

7. The method of claim 1 , wherein the antibody that specifically binds to epidermal growth factor receptor is selected from the group consisting of cetuximab, panitumumab, nimotuzumab, zalutumumab and matuzumab.

Assignees

• Univ Leland Stanford Junior

Inventors

• Weissman Irving L
• Willingham Stephen
• Ho Doris Po Yi
• Dalerba Piero D
• McKenna Kelly Marie
• Volkmer Jens-Peter

Classifications

• A61K2039/507

  Comprising a combination of two or more separate antibodies · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/75

  Agonist effect on antigen · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title